# Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria

> **NCT06848296** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Bisirna Therapeutics Pte. Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** VSA012

## Key facts

- **NCT ID:** NCT06848296
- **Lead sponsor:** Bisirna Therapeutics Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-08-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848296, "Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal Hemoglobinuria". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06848296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*